Physician profile
Richard E Rochester
NPI 1902802523
$6,996.63
in general payments reported to CMS, 2019-2025
32 companies · $949 in 2025
The $949 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $582 · 2021: $1,135 · 2022: $960 · 2023: $877 · 2024: $1,056 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $763.66 | 2019-2025 | Trintellix |
| Abbvie INC. | $585.15 | 2021-2025 | Vraylar |
| Neos Therapeutics, LP | $530.85 | 2019-2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $467.44 | 2019-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $455.33 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $442.53 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $369.65 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $367.39 | 2019-2024 | Hetlioz, Fanapt |
| Lundbeck LLC | $360.88 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $343.60 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $277.12 | 2022-2025 | Ingrezza |
| Corium, LLC | $260.73 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $217.29 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $179.56 | 2019-2022 | |
| Tris Pharma INC | $169.03 | 2022-2025 | Dyanavel Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $162.93 | 2019-2020 | |
| Eisai INC. | $148.14 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $146.79 | 2019-2022 | |
| Noven Therapeutics, LLC | $129.13 | 2024-2025 | Xelstrym, Secuado |
| Rigel Pharmaceuticals, INC. | $127.20 | 2024 | Tavalisse, Rezlidhia |
| Adlon Therapeutics L.P. | $92.43 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $88.38 | 2019-2023 | Jornay Pm |
| Neuronetics, INC. | $57.38 | 2019-2020 | |
| Alkermes, INC. | $56.20 | 2023-2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $52.86 | 2024 | Quviviq |
| Shire North American Group INC | $46.23 | 2019 | |
| Merck Sharp & Dohme LLC | $24.80 | 2021-2022 | |
| Almatica Pharma LLC | $23.33 | 2021-2022 | |
| Tempus Ai, INC | $17.64 | 2024 | |
| Arbor Pharmaceuticals, INC. | $16.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.21 | 2022 | |
| Aytu Biopharma, INC. | $4.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rochester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.